
Viridian Therapeutics (VRDN) Stock Forecast & Price Target
Viridian Therapeutics (VRDN) Analyst Ratings
Bulls say
Viridian Therapeutics is expected to benefit from the positive results of elegrobart in clinical trials and the company's strong financial position and expanding pipeline. However, competition in the market and a lowered target price may pose challenges for the company's success. Despite these challenges, Viridian Therapeutics has the potential for success in the future and its differentiated drug, elegrobart, may serve as a promising treatment option for patients with thyroid eye disease.
Bears say
Viridian Therapeutics is developing two anti-IGF-1R product candidates for the treatment of thyroid eye disease, but there are several potential concerns surrounding the company. First, the dosing regimen for veligrotug may be burdensome for patients, requiring 12 infusions over 22 weeks. Additionally, there is still incomplete data available for the company's other product candidate, elegrobart. Furthermore, Viridian faces sustainability issues, including data transparency and diversity of management, that may hinder its long-term success. These risks, along with potential competition and manufacturing challenges, make for a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares